Search

Interpreting animal behavior in the context of welfare can be inherently challenging given the limited behavior data available for many species housed in zoos. Describing common behavior patterns may help animal managers by providing additional background when assessing the individuals in their care. Although valuable, these efforts require a large, collaborative approach and have, consequently, been rare. Here, we share the behavior patterns of zoo-housed giraffes, an iconic and commonly housed megafauna in zoos. Behavior data were evaluated for 66 giraffes living across 18 AZA-accredited zoos using the ZooMonitor Community platform. Data were recorded during 10-minute observation sessions. Observations were conducted during daytime hours over the course of approximately one year at each zoo (mean total observed time per individual = 23.2 hr). The most common behaviors observed were feeding/ foraging behaviors, which accounted for 38.6% of the mean visible time budget across giraffes. Time spent in these behaviors varied by individual and ranged from 14.3% to 69.3% of visible time. Stereotypic behaviors occurred in all study individuals, with oral stereotypic behaviors being most common. Although prevalent, stereotypic behaviors varied considerably across giraffes, with some individuals exhibiting these behaviors only on a few occasions to an individual that exhibited these behaviors once every few minutes. This study provides a robust evaluation of giraffe behavior across zoos to present a picture of their common behavior patterns in managed care. We hope these multi-institutional behavior patterns can provide perspective to aid animal managers in evaluating giraffes in their care., Competing Interests: The authors declare there are no competing interests., (©2024 Wark and Cronin.)

Objective: To prospectively measure cardiometabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy (RRBSO) compared to a similar age comparison group, and the effects of Hormone Therapy (HT) on cardiometabolic risk., Methods: Prospective observational study of 95 premenopausal women planning RRBSO and 99 comparisons who retained their ovaries. At baseline and 12 months, blood pressure (BP), Body Mass Index (BMI), waist and hip circumference, fasting total, HDL and LDL cholesterol, triglycerides, high-sensitivity C-reactive protein, glucose and insulin were measured and HOMA-IR was calculated. Chi-square tests, t-tests and adjusted logistic regression models were used to compare groups., Results: Baseline cardiometabolic phenotypes were similar between groups but more RRBSO participants were overweight/obese with higher waist/hip ratios. By 12 months, BP and cardiometabolic phenotypes were largely unchanged. Paired t-tests showed statistically significant increases in BMI (p = 0.037) and weight (p = 0.042) and larger increases in waist circumference (p < 0.001) and waist-hip ratio (p = 0.009) after RRBSO vs comparisons. However, these were not significant when adjusted for baseline values. After RRBSO 60% initiated Hormone Therapy (HT). Paired t-tests demonstrated that non-HT users had a significantly greater mean increase in waist circumference of 4.3 cm (95% CI 2.0-6.5) compared to 1.3 cm in HT users (95% CI -0.2-2.7, p < 0.001), which remained significant when adjusted for baseline values (p = 0.02). At 12 months, mean waist circumference was 2.94 cm greater in non-HT users compared to HT users., Conclusions: Cardiometabolic risk markers are largely unchanged 12 months after RRBSO. Hormone Therapy after RRBSO may prevent against an increase in waist circumference., Competing Interests: Declaration of Competing Interest MH is an editor for the Cochrane Collaboration Group and has received pharmaceutical funding from QUE Oncology P/L, Madorra P/L and Ovoca Bio (Australia) P/L for clinical trials outside of the submitted work. SMD has received personal fees from AstraZeneca outside of the submitted work. KMM, GDM, EOK, AT and RAW have no conflicts of interest to declare., (Copyright © 2021. Published by Elsevier Inc.)